Markets:

Overview

News

Currencies

International

Treasuries

Atara Biotherapeutics, Inc. - Common Stock (NQ:ATRA)

18.07 +0.07 (+0.36%)

Streaming Delayed Price Updated: 12:33 PM EST, Dec 15, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Atara Biotherapeutics, Inc. - Common Stock

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Atara Biotherapeutics Presents Updated Tab-cel® Clinical Effectiveness Data at ASCO 2023

June 05, 2023

From Atara Biotherapeutics, Inc.

Via Business Wire

Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 02, 2023

From Atara Biotherapeutics, Inc.

Via Business Wire

Atara Biotherapeutics Earnings Perspective: Return On Capital Employed ↗

May 23, 2023

Via Benzinga

A Preview Of Atara Biotherapeutics's Earnings ↗

May 05, 2023

Via Benzinga

Looking Into Atara Biotherapeutics's Return On Capital Employed ↗

February 10, 2023

Via Benzinga

Why PRA Group Shares Are Trading Lower By 44%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

May 09, 2023

Gainers TScan Therapeutics, Inc. (NASDAQ: TCRX) shares gained 118% to $4.68 after the company and Amgen announced collaboration to identify novel targets in Crohn's disease.

Via Benzinga

Atara Biotherapeutics Announces First Quarter 2023 Financial Results and Operational Progress

May 08, 2023

From Atara Biotherapeutics, Inc.

Via Business Wire

Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 05, 2023

From Atara Biotherapeutics, Inc.

Via Business Wire

Atara Biotherapeutics to Announce First Quarter 2023 Financial Results on Monday, May 8, 2023

May 01, 2023

From Atara Biotherapeutics, Inc.

Via Business Wire

3 Stocks to Buy That Could Be the Next Biotech Breakthrough ↗

April 16, 2023

Biotech stocks are highly speculative, but it's possible to choose ones with excellent risk-reward ratios.

Via InvestorPlace

Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

March 31, 2023

From Atara Biotherapeutics, Inc.

Via Business Wire

Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

March 03, 2023

From Atara Biotherapeutics, Inc.

Via Business Wire

Atara Biotherapeutics to Participate in Cell Therapy Panel Discussion at the Cowen 43rd Annual Health Care Conference

March 01, 2023

From Atara Biotherapeutics, Inc.

Via Business Wire

Atara Biotherapeutics to Participate in the H.C. Wainwright Cell Therapy Virtual Conference

February 21, 2023

From Atara Biotherapeutics, Inc.

Via Business Wire

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

February 08, 2023

Via Benzinga

Atara Biotherapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Operational Progress

February 08, 2023

From Atara Biotherapeutics, Inc.

Via Business Wire

Pierre Fabre to Commercialize and Distribute the First Approved Allogeneic T-cell Immunotherapy in Europe Following Transfer of the European Commission Marketing Authorization of EBVALLO™ (tabelecleucel)

February 08, 2023

From Atara Biotherapeutics, Inc.

Via Business Wire

Why Bed Bath & Beyond Fell Almost 30%; Here Are 20 Stocks Moving Premarket ↗

February 07, 2023

Gainers

Via Benzinga

Atara Biotherapeutics to Announce Fourth Quarter and Full Year 2022 Financial Results on Wednesday, February 8, 2023

February 06, 2023

From Atara Biotherapeutics, Inc.

Via Business Wire

Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

February 03, 2023

From Atara Biotherapeutics, Inc.

Via Business Wire

Atara Biotherapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

January 13, 2023

From Atara Biotherapeutics, Inc.

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2023 ↗

January 05, 2023

Via Benzinga

Atara Biotherapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

January 04, 2023

From Atara Biotherapeutics, Inc.

Via Business Wire

Li Auto, XPeng, Nio And Some Other Big Stocks Moving Higher In Today's Pre-Market Session ↗

January 03, 2023

U.S. stock futures traded higher this morning. Here are some big stocks recording gains in today’s pre-market trading session.

Via Benzinga

3 Under-the-Radar Biotech Stocks to Buy in 2022 ↗

December 24, 2022

The attraction of all three biotech stocks is their potential.

Via The Motley Fool

Atara Biotherapeutics Announces $31 Million Royalty Interest Financing Agreement with HealthCare Royalty

December 20, 2022

From Atara Biotherapeutics, Inc.

Via Business Wire

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

December 20, 2022

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tueday ↗

December 20, 2022

We're starting off the day with a breakdown of the biggest pre-market stock movers traders need to know about on Tuesday morning!

Via InvestorPlace

Atara Biotherapeutics Announces Changes to Its Board of Directors

December 19, 2022

From Atara Biotherapeutics, Inc.

Via Business Wire

Atara Biotherapeutics’ Ebvallo™ (tabelecleucel) Receives European Commission Approval as First Ever Therapy for Adults and Children with EBV+ PTLD

December 19, 2022

From Atara Biotherapeutics, Inc.

Via Business Wire

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Atara Biotherapeutics, Inc. - Common Stock (NQ:ATRA)

All News about Atara Biotherapeutics, Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today